TorreyPines Therapeutics announced that it has agreed to sell its Alzheimer's disease genetics research program to Eisai Co.for an upfront cash payment.

Financial terms of the deal were not disclosed

TorreyPines and Eisai have collaborated on the genetics program since 2002, with the most recent agreement between the parties concluding on September 30, 2008. The Alzheimer's disease genetics research program focused on the discovery of Alzheimer's disease targets using whole-genome family-based association screening.